Clinical Trial Update: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for a Bruton's Tyrosine Kinase inhibitor in relapsed/refractory marginal zone lymphoma and B-cell lymphoma has completed; results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Bruton's Tyrosine Kinase inhibitor

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Marginal Zone Lymphoma, B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-10